Law360, New York (September 19, 2008, 12:00 AM EDT) -- The U.S. House of Representatives Committee on Energy and Commerce has expanded its probe of Ranbaxy Laboratories, with lawmakers demanding to take a deeper look at the president's emergency program for AIDS relief, which may have been compromised by alleged manufacturing deficiences at two plants in India.
On Thursday, committee chairman Rep. John D. Dingell, D-Mich., revealed that other congressional members had joined the investigation into Ranbaxy, which came under fire earlier this week.
On Tuesday, the U.S. Food and Drug Administration barred more than 30...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.